Learn More
Beschreibung
Methotrexate is actively transported into cells by the folate transporter. In the cell, it is converted to a high molecular weight polyglutamate metabolite by folypolyglutamate synthase that, in turn, binds to dihydrofolate reductase and inhibits its activity. Methotrexate-polyglutamate is degraded intracellularly by gamma-glutamyl hydrolase.
Methotrexate is an allosteric inhibititor of dihydrofolate reductase (DHFR), the enzyme that catalyzes the conversion of dihydrofolate to tetrahydrofolate. Since tetrahydrolfolate is required for purine and pyrimidine synthesis, methotrexate treatment results in the inhibition of DNA and RNA synthesis.
- Potent inhibitor of dihydrofolate reductase in DHFR-based protein expression systems
- Anti-cancer agent used in antitumor studies
- Effective in treatment of pyrimethamine-resistant Plasmodium vivax malaria parasites
- Shows immunosuppressive effects, e.g. in rheumatoid arthritis
Spezifikation
Spezifikation
| Melting Point | 185°C to 204°C |
| Boiling Point | 184°C to 204°C (monohydrate decomposition) |
| Quantity | 10 mg |
| Solubility Information | Soluble in alkaline solutions with decomposition.Insoluble in water, ethanol, chloroform and ether. |
| Optical Rotation | 19–24° |
| Formula Weight | 454.4 |
| Grade | USP |
| Physical Form | Powder |
Indem Sie auf Absenden klicken, erklären Sie sich damit einverstanden, dass Fisher Scientific sich mit Ihnen in Verbindung setzen kann, um Ihr Feedback in diesem Formular zu bearbeiten. Wir werden Ihre Informationen nicht für andere Zwecke weitergeben. Alle bereitgestellten Kontaktinformationen werden in Übereinstimmung mit unserer Datenschutzrichtlinie aufbewahrt. Datenschutzrichtlinie.